In this blog, Jill Hagenkord, MD, outlines the evidence needed to achieve widespread clinical adoption and reimbursement coverage for new medical devices from a private insurer’s perspective.
This blog is adapted from Dr. Hagenkord’s special lecture at the 2022 Symposium.
“Available technologies cannot reach the regions of the brain involved in psychiatric disorders. This is where focused ultrasound comes into play. If the results of this study are positive, the data will serve as a strong foundation for the future development of innovative treatments for a variety of psychiatric disorders.”